Urica Therapeutics

Urica Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for gout and other conditions associated with hyperuricemia. Their lead product, dotinurad, is a potential best-in-class urate transporter (URAT1) inhibitor that can lower blood uric acid levels by selectively inhibiting URAT1 and uric acid reabsorption in the kidneys. It is currently in clinical development for the treatment of gout. Urica Therapeutics is developing treatments to manage and prevent gout attacks, a painful condition caused by the accumulation of uric acid crystals in the joints. They are also exploring the potential of their therapies to address other conditions associated with elevated uric acid levels, such as chronic kidney disease and heart failure. Urica Therapeutics' innovative approach has the potential to revolutionize the treatment of gout and other hyperuricemic conditions by providing effective and well-tolerated therapies.

Jobs: